ArchiveApril 2015

What’s in a Name? 30th

This week it is MS awareness week in the United Kingdom Scientists and Neuros and health care professionals write papers every day and you are increasingly getting to see them with open source information. It is interesting how they refer to you in these papers and grants. Maybe it is time you said what you prefer.  What’s In Name? We have asked this before and now I am asking this...

Effects of MS on Walking

Lizrova Preiningerova J, Novotna K, Rusz J, Sucha L, Ruzicka E, Havrdova E. Spatial and temporal characteristics of gait as outcome measures in multiple sclerosis (EDSS 0 to 6.5).J Neuroeng Rehabil. 2015;12(1):14. BACKGROUND:Gait impairment represents one of the most common and disabling symptom of multiple sclerosis. Quantification of the gait is an important aspect of clinical trials. In...

Neuroprotection from Testosterone

How believable is the data hinting that testosterone has neuroprotective effects? #MSBlog #MSResearch “At first glance this small exploratory trial of testosterone in men produces some interesting data and suggests it is neuroprotective in men with MS. Problems? The variability of MRI brain atrophy typically requires 60-80 subjects per arm in a 2 year study to discern a meaningful outcome...

Gilenya use in the Real Word

Ramseier SP, Roth S, Czaplinski A. A Swiss real world best practice experience in three different clinical settings of the 6 hour fingolimod first dose observation procedure.BMC Pharmacol Toxicol. 2015;16(1):7. [Epub ahead of print] BACKGROUND:The Swiss label of oral fingolimod (0.5 mg once daily) requires a 6-hour first dose observation (FDO) including an ECG prior to and 6 hours after the first...

Whats in a Name 29th

This week it is MS awareness week in the United Kingdom Scientists and Neuros and health care professionals write papers every day and you are increasingly getting to see them with open source information. It is interesting how they refer to you in these papers and grants. Maybe it is time you said what you prefer.  What’s In Name? We have asked this before and now I am asking this...

Blocking microglial could this affect progression

Savarin C, Hinton DR, Valentin-Torres A, Chen Z, Trapp BD, Bergmann CC, Stohlman SA.Astrocyte response to IFN-γ limits IL-6-mediated microglia activation and progressive autoimmune encephalomyelitis.J Neuroinflammation. 2015;12(1):79. [Epub ahead of printBACKGROUND:Therapeutic modalities effective in patients with progressive forms of multiple sclerosis (MS) are limited. In a murine model of...

Whats in Name 28th

This week it is MS awareness week in the United Kingdom Scientists and Neuros and health care professionals write papers every day and you are increasingly getting to see them with open source information. It is interesting how they refer to you in these papers and grants. Maybe it is time you said what you prefer.  What’s In Name? We have asked this before and now I am asking this...

Translate

Categories

Recent Posts

Recent Comments

Archives